Cushings Syndrome Pipeline Assessment Focusing on Therapeutic Drugs, Market Outlook for H1 2018

Published on : Jun 27, 2018

Albany, New York, June 27, 2018: Market Research Hub (MRH) has included a new extensive and fact-based research publication on Cushing's syndrome in its extensive research database. The research study is titled as “Cushings Syndrome - Pipeline Review, H1 2018” which encapsulated complete information and facts pertaining to Cushing syndrome therapeutic areas, with details on the various developmental stages, mechanisms in action, route of administration, and type of molecule. The report also features a few of the key players working on cushings syndrome therapeutic development and provides information and updates on activities and also the dormant and discontinued projects.

In the first part, this pipeline guide starts by presenting a detailed overview of cushings syndrome. Cushing syndrome occurs due to irregularly high levels of the hormone cortisol. It is a severe disease which can be long-term and may be life-threatening because of the various complications associated with it such as, diabetes, high blood pressure and mental problems. Some of the common symptoms of the disease include obesity, roundish face, easy stain, excessive growth of coarse hair on the face, weakening of the bones, growth of fat above the collar bone and the back of the neck. At present, treatment includes surgery and medications to control excessive production of cortisol.

Moreover, the report reflects drug profiles for the products in the pipeline that involves product description, research and development briefing, descriptive mode of administration (MoA), collaboration and licensing details as well as various development activities. The report also assesses all the discontinued as well as dormant projects during this timeline. The report further also adds an examination of the latest deals and news associated with Cushings syndrome targeted therapeutics.

At last, the companies listed in the review report that deal with therapeutic development for Cushing syndrome are Angion Biomedica Corp., ElexoPharm GmbH, Orphagen Pharmaceuticals Inc., AstraZeneca Plc., Reset Therapeutics Inc., Strongbridge Biopharma plc., Hybrigenics SA, Corcept Therapeutics Inc., Novartis AG, Diurnal Group Plc and Millendo Therapeutics Inc. This research report includes details of the above-mentioned companies, such as their product portfolios, financials, SWOT etc.

Reasons to Invest in this Report

This research report can assist in the expansion of business by potentially increasing the scope of business through designing and developing the out-licensing and in-licensing strategies by classifying prospects with highly attractive projects.

The data enclosed in the report has been sourced from different proprietary database, including investor presentations, clinical trial strategies, press releases, and third-party information sources. The scope of the report is quite comprehensive, and it offers readers complete information on the pipeline projects that are currently under review.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top